Yinhua CSI Innovative Drugs Industry ETF

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Norges Bank Increases Holding of Tigermed to 813,800 Shares

159892

ARKG

512290

159316

516500

SBIO

588130

159849

159837

Harbour BioMed announced promising preclinical data for LET003, its first AI-enabled drug candidate targeting obesity. LET003 demonstrated superior pharmacokinetics and enhanced fat reduction when combined with semaglutide, while preserving lean mass. The results suggest LET003 could be a best-in-class therapy for obesity, achieving significant fat loss and lean mass improvement at lower doses compared to competitors. The findings were supported by the company's Hu-mAtrIx™ AI platform, indicating strong potential for future development.

prnewswire

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ark Genomic Revolution ETF

Guotai CSI Bio-medicine ETF

iShares Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

VG Health

iShares US Pharma

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

E Fund CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Bosera Hang Seng Health Care ETF(QDII)

HBM HOLDINGS-B

20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate

603259

02359

UBS reported that WUXI APPTEC announced the issuance of RMB6.78 billion one-year zero-coupon convertible bonds at 103.5% of the principal amount. The initial conversion price is HKD153 per share, a 17.6% premium over the previous closing price. UBS views this as slightly positive, reflecting management's confidence, and has set a target price of HKD171.2 with a Buy rating.

AASTOCKS News

WuXi AppTec

WUXI APPTEC

UBS Group AG

UBS: WUXI APPTEC  Zero-Coupon Convertible Bond Issuance Slightly Positive, Reflects Management Confidence

01801

159570

Innovent Biologics showcased its next-generation bispecific antibodies at the 2026 ATS and ARVO Conferences. Key presentations included IBI3002, targeting IL-4Rα/TSLP for asthma, IBI3038 for lung fibrosis, and IBI3031 for Thyroid Eye Disease. These candidates demonstrated promising preclinical and clinical results, indicating potential for improved therapeutic efficacy in autoimmune and ophthalmological diseases.

INNOVENT BIO

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

20:00 ETInnovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences

Fingerprint Cards AB reported a mixed Q1 earnings call, highlighting a 4% revenue growth and a 62.3% gross margin, despite challenges like negative EBITDA and tight cash. The company is banking on a merger with Precise Biometrics to address its subscale cost base, aiming for significant annual cost synergies. AllKey platform is emerging as a key growth driver, representing 75% of the Q1 pipeline. However, the company faces liquidity pressures and must successfully execute the merger to achieve sustainable profitability.

Tip Ranks

Fingerprint Cards AB Bets on Merger-Led Turnaround

Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.

PUBT

iShares Global Healthcare

Penghua CSI HK Connect Health Care Composite ETF

BlackRock, Inc.

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer

516820

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

600276

M Stanley reports that HENGRUI PHARMA has formed a USD15.2 billion strategic partnership with Bristol-Myers Squibb, covering 13 pre-clinical assets. The deal includes a USD600 million upfront payment, annual payments of USD350 million for 2027-2028, and up to USD14.3 billion in milestone payments. This collaboration is expected to enhance HENGRUI's R&D and globalization capabilities, particularly in the immunology market in China. M Stanley maintains an Overweight rating on HENGRUI PHARMA with a target price of HKD92 for its H shares.

Hengrui Pharma

Bristol Myers Squibb

Morgan Stanley

HENGRUI PHARMA

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Bristol-Myers Squibb Company

M Stanley: HENGRUI PHARMA  Forms USD15.2B Strategic Partnership with Bristol-Myers Squibb Company  to Accelerate Globalization

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

ProShares Ultra Health Care ETF

Direxion Pharma & Medical Bull 3X

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

01276

HENGRUI PHARMA has entered a global strategic collaboration and license agreement with Bristol-Myers Squibb Company to advance 13 early-stage programs in oncology, hematology, and immunology. The agreement includes payments up to USD950 million, with an upfront payment of USD600 million and additional payments in the following years. The total deal value could reach approximately USD15.2 billion, contingent on co-development options and milestone achievements.

HENGRUI PHARMA  and Bristol-Myers Squibb Company  Enter Global Strategic Collaboration and License Agreement, Eligible for USD950 million in Related Payments

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

Microbiotica reports positive results for MB097 in advanced melanoma

Yinhua CSI Innovative Drugs Industry ETF(159992.SZ)